How to Cite
Abstract
ObjectiveOcular surface squamous neoplasia (OSSN) encompasses a spectrum of malignancies affecting the conjunctival and corneal tissues, including conjunctival intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC). High recurrence rates for OSSN necessitate effective treatment strategies, particularly in low-resource settings.
MethodologyThis prospective case series, conducted from March 2023 to March 2024 at the Department of Orbit and Oculoplastics, Alshifa Trust Eye Hospital, Rawalpindi, included 34 eyes from 34 patients with biopsy-confirmed OSSN. Patients underwent surgical excision with a 4 mm clear margin, followed by applying 1% 5-fluorouracil (5-FU) for 90 seconds and cryotherapy using a double freeze-thaw cycle. Post-surgical patients received topical 5-FU in cycles: one week on and three weeks off, for three to five months. Outcomes were documented through clinical examination and anterior segment optical coherence tomography (OCT). Primary outcomes were recurrence of clinical lesions. The secondary outcome was detecting the presence of HIV in patients by using an HIV antibody titres assay.
ResultsThe mean age of patients was 53.3 years. 73.5% were males, and 26.5% were females. The majority (76.5%) were diagnosed with full-thickness dysplasia. Treatment was predominantly post-excision. Chemoreduction prior to surgery was done in 4 patients. Most had 3 cycles of 5-FU (52.9%). During follow-up, not a single recurrent lesion occurred. Logistic regression indicated a positive, though non-significant, association between the number of 5-FU cycles and reduced recurrence (β = 0.2598, p = 0.321).
ConclusionThis study demonstrates that using 5-FU with cryotherapy significantly reduces OSSN recurrence in low-resource settings. Further research with larger cohorts is recommended to confirm these findings and refine treatment protocols.
Keywords5-Fluorouracil, Cryotherapy, chemotherapy protocols, Squamous Cell neoplasm, Conjunctival disease
References
Hollhumer R, Williams S, Michelow P. Ocular surface squamous neoplasia: Population demographics, pathogenesis and risk factors. African Vision and Eye Health. 2020 Jun 23;79(1) DOI: https://doi.org/10.4102/aveh.v79i1.553 |
.Darwich R, Ghazawi FM, Le M, Rahme E, Alghazawi N, Zubarev A, et al. Epidemiology of invasive ocular surface squamous neoplasia in Canada during 1992–2010. British Journal of Ophthalmology. 2020 DOI: 10.1136/bjophthalmol-2019-314650
Odendaal LN, Andreae C, Sanderson-November M, Zaharie D, Smit DP. The prevalence of human papillomavirus in ocular surface squamous neoplasia in HIV positive and negative patients in a South African population. Infection. 2024 May 9;
Höllhumer R, Michelow P, Williams S. Demographics, clinical presentation and risk factors of ocular surface squamous neoplasia at a tertiary hospital, South Africa. 2023 May 31
Shimizu N, Toshiyuki Oshitari, Jiro Yotsukura, Hirotaka Yokouchi, Baba T, Yamamoto S. Ten-year epidemiological study of ocular and orbital tumors in Chiba University Hospital. BMC Ophthalmology [Internet]. 2021 Sep 23 [cited 2024 Feb 29];21(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459513/
Sripawadkul W, Theotoka D, Zein M, Galor A, Karp CL. Conjunctival papilloma treatment outcomes: a 12-year-retrospective study. Eye. 2022 Dec 5;37(5):977–82
Patel U, Karp CL, Dubovy SR. Update on the Management of Ocular Surface Squamous Neoplasia. Current Ophthalmology Reports. 2021 Feb 20;9(1):7–15.. DOI: 10.1007/s40135-020-00260-y
Suleiman DE, Liman AA, Waziri GD, Iliyasu Y, Ahmed SA. Clinicopathological characteristics of ocular surface squamous neoplasia: a 10-year review form a referral tertiary centre in Nigeria. International Ophthalmology. 2022 Jul 8;42(12):3905–11.
Ocular Surface Squamous Neoplasia: Clinicopathological Analysis and Treatment Outcome of 65 Cases. Journal of the College of Physicians and Surgeons Pakistan. 2020 Sep 1;31(09):970–3..
Ju X, Gaca P, Fan W, Rokohl AC, Guo Y, Wawer PA, et al. Therapy Failure and Resistance Mechanism in Eyelid and Ocular Surface Tumors. PubMed. 2022 Aug 25;30(S1):21–38
Savino G, Cuffaro G, Maceroni M, Monica Maria Pagliara, Maria Grazia Sammarco, Giraldi L, et al. Advanced ocular surface squamous cell carcinoma (OSSC): long-term follow-up. Graefes Archive for Clinical and Experimental Ophthalmology. 2021 Jul 20;259(11):3437–4
Singh A, Sharma A, Srivastava S, Jaiswal A, Mere K, Dixit H, et al. Cytomorphological Spectrum of Ocular Surface Squamous Neoplasia in Elderly Age Group and Its Clinicopathological Correlation. Journal of Pharmacy And Bioallied Sciences. 2024 Jul
.Nakai H, Ueda K, Koji Kitazawa, Fukuoka H, Tsutomu Inatomi, Yokoi N, et al. Excision combined with ocular surface reconstruction followed by topical chemotherapy for ocular surface squamous neoplasia. Japanese Journal of Ophthalmology. 2024 Oct 2
Bowen, R.C.; Soto, H.; Raval, V.; Bellerive, C.; Yeaney, G.; Singh, A.D. Ocular Surface Squamous Neoplasia: Outcomes Following Primary Excision with 2 Mm Margin and Cryotherapy. Eye 2021, 35, 3102–3109.
.Greenfield JA, Cohen AK, Galor A, Chodosh J, Stone D, Karp CL. Ocular Surface Squamous Neoplasia: Changes in the Standard of Care 2003 to 2022. Cornea. 2024 Jan 18;43(8):942–9
Leventer I, Singh H, Bahram Pashaee, Raimondo CD, Khakh CK, Martin JL, et al. Topical 5-fluorouracil 1% for moderate to extensive ocular surface squamous neoplasia in 73 consecutive patients: Primary versus secondary treatment. Asia-Pacific Journal of Ophthalmology. 2024 Mar 1;13(2):100052–2.
Bowen RC, Soto H, Raval V, Bellerive C, Yeaney G, Singh AD. Ocular surface squamous neoplasia: outcomes following primary excision with 2 mm margin and cryotherapy. Eye. 2021 Jan 19;35(11):3102–9.
Teixeira GC, Resende MI, Morales MC, Fernandes AG. Topical 5-Fluorouracil 0.5% as primary treatment for Ocular Surface Squamous Neoplasia. Eur J Ophthalmol. 2024. doi: 10.1177/11206721241256687.
Gurnani B, Kaur K. Current concepts and recent updates in the treatment of ocular surface squamous neoplasia. Expert Rev Ophthalmol. 2023;18(5):281-287.
Patel SC, Galor A. Outcomes of the ocular surface squamous neoplasia following primary excision with narrow margins and cryotherapy. Cornea. 2021;40(5):565-572.
Kozma K, Dömötör ZR, Csutak A, Szabó L, Hegyi P, Erőss B, et al. Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis. Scientific Reports. 2022 Aug 20;12(1)
Monroy D, Serrano A, Galor A, Karp CL. Medical treatment for ocular surface squamous neoplasia. Eye [Internet]. 2023 Feb 8;1–9. Available from: https://www.nature.com/articles/s41433-023-02434-x.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) 2025 Sumeya Ali Khan, Saad Ullah, Amna Manzoor, Fariha Taimur, Faizan Tahir, Murtaza Sameen